SCD1 inhibitor-3

Research use only, not for human use.

SCD1 inhibitor-3 (ML-270) is a highly effective and orally available compound that inhibits SCD1 with remarkable safety.

SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.

——

SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index.Animal Model:Lewis rats Dosage:5 mg/kg Administration:P.o.; 4 hours Result:Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %.Animal Model:Lewis rats Dosage:2~10 mg/kg Administration:P.o.; 4 hours Result:A dose-responsive reduction of plasma triglycerides desaturation index.

——

Metabolic Enzyme/Protease

Dehydrogenase

Dehydrogenase

——

——

1282606-48-7

393.37

C19H16FN7O2

>98% (HPLC)

In Vitro:?DMSO : ≥ 125 mg/mL (317.77 mM)

Fc1ccc(Cn2ncn(-c3cc(n[nH]3)C(=O)NCc3cccnc3)c2=O)cc1

——

(-20℃)

With Ice Pack

≥ 2 years